<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5461628</article-id><article-id pub-id-type="publisher-id">553</article-id><article-id pub-id-type="doi">10.1186/s12933-017-0553-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jing-Wei</given-names></name><address><email>jingwei6829@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Yun-Dai</given-names></name><address><phone>+8610-66939709</phone><email>cyundai@vip.163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wei-Ren</given-names></name><address><email>chen_weiren@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>You</surname><given-names>Qi</given-names></name><address><email>youyou2x@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Bo</given-names></name><address><email>22401919@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hao</given-names></name><address><email>zhouhao301@outlook.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Ying</given-names></name><address><email>1011716765@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Tian-Wen</given-names></name><address><email>tianwenhanhan@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1761 8894</institution-id><institution-id institution-id-type="GRID">grid.414252.4</institution-id><institution>Department of Cardiology, </institution><institution>People&#8217;s Liberation Army General Hospital, </institution></institution-wrap>No. 28 Fuxing Road, Wukesong, Haidian District, Beijing, 100853 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1760 6682</institution-id><institution-id institution-id-type="GRID">grid.410570.7</institution-id><institution>Department of Cardiology, Xinqiao Hospital, </institution><institution>Third Military Medical University, </institution></institution-wrap>Chongqing, China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><elocation-id>72</elocation-id><history><date date-type="received"><day>6</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#169; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Dipeptidyl peptidase-4 (DPP4) regulates blood glucose levels and inflammation, and it is also implicated in the pathophysiological process of myocardial infarction (MI). Plasma DPP4 activity (DPP4a) may provide prognostic information regarding outcomes for ST-segment elevation MI (STEMI) patients.</p></sec><sec><title>Methods</title><p>Blood samples were obtained from 625 consecutively admitted, percutaneous coronary intervention-treated STEMI patients with a mean age of 57&#160;years old. DPP4a was quantified using enzymatic assays.</p></sec><sec><title>Results</title><p>The median follow-up period was 30&#160;months. Multivariate Cox-regression analyses (adjusted for confounding variables) showed that a 1&#160;U/L increase of DPP4a did not associate with risks of major adverse cardiac or cerebrovascular events (MACCE), cardiovascular mortality, MI, heart failure readmission, stroke, non-cardiovascular mortality and repeated revascularization. However, in a subset of 149 diabetic STEMI patients, DPP4a associated with an increased risk of MACCE (HR 1.16; 95% CI 1.04&#8211;1.30; <italic>p</italic>&#160;=&#160;0.01).</p></sec><sec><title>Conclusions</title><p>DPP4a did not associate with cardiovascular events and non-cardiovascular mortality in non-diabetic STEMI patients. However, DPP4a may be associated with future MACCE in diabetic STEMI patients.</p><p>
<italic>Trial registration</italic> NCT03046576, registered on 5 February, 2017, retrospectively registered</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12933-017-0553-3) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dipeptidyl peptidase 4</kwd><kwd>ST elevation myocardial infarction</kwd><kwd>Cardiovascular system</kwd><kwd>Biomarkers</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>China Postdoctoral Science Foundation</institution></funding-source><award-id>2016M603025</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Jing-Wei</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Pilot Foundation of the Beijing Lisheng Cardiovascular Health Foundation</institution></funding-source><award-id>LHJJ201611827</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Jing-Wei</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Dipeptidyl peptidase 4 (DPP4) was identified as a cell surface protein that cleaved amino-terminal dipeptides containing either <sc>l</sc>-proline or <sc>l</sc>-alanine at the second to last position. DPP4 inactivated glucagon-like peptide-1 (GLP-1), a member of the incretin metabolic hormone family, thus involving it in glucose metabolism [<xref ref-type="bibr" rid="CR1">1</xref>]. Widespread expression of DPP4 on the surface of myocardial and endothelial cells, and the non-enzymatic function of it as a signaling and binding protein suggest a function in cardiovascular regulation [<xref ref-type="bibr" rid="CR2">2</xref>]. Data elucidating a potential role for DPP4 in heart failure (HF) have conflicted. The DPP4 inhibitor saxagliptin led to a 27% increase in hospitalization for HF in diabetic patients who had a history of, or were at risk for, cardiovascular events [<xref ref-type="bibr" rid="CR3">3</xref>]. Use of a DPP4 inhibitor associated with reduced risk of hospitalization for HF when compared with patients receiving antidiabetic sulphonylurea drugs [<xref ref-type="bibr" rid="CR4">4</xref>]. A recent meta-analysis showed that the relative effects of DPP4 inhibitors on HF risk were uncertain [<xref ref-type="bibr" rid="CR5">5</xref>]. Conversely, the role of DPP4 in myocardial infarction (MI) was largely consistent across studies. DPP4 inhibition during MI events played a protective role. Either genetic disruption or chemical inhibition of DPP4 improved functional recovery after ischemia/reperfusion injury in an animal MI model [<xref ref-type="bibr" rid="CR6">6</xref>], and DPP4 inhibitors improved left ventricular diastolic function in diabetic patients with acute MI [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>DPP4 also exists in a soluble form in the plasma, where it is thought to be shed from the membranes of endothelial cells, while maintaining enzymatic activity [<xref ref-type="bibr" rid="CR8">8</xref>]. Increased plasma DPP4 activity (DPP4a) predicted both sub-clinical and new-onset atherosclerotic events [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Additionally, DPP4a correlated with adverse cardiovascular outcomes in HF [<xref ref-type="bibr" rid="CR11">11</xref>] as well as sub-clinical left ventricular dysfunction in diabetic patients [<xref ref-type="bibr" rid="CR12">12</xref>]. Our previous work found that DPP4a was significantly lower in MI patients compared with patients experiencing only chest pain or unstable angina, and DPP4a associated with inpatient no-reflow and major bleeding events in STEMI patients [<xref ref-type="bibr" rid="CR13">13</xref>]. The no-reflow phenomenon [<xref ref-type="bibr" rid="CR14">14</xref>] and major bleeding events [<xref ref-type="bibr" rid="CR15">15</xref>] independently associated with worsened in-hospital and long-term prognoses. Thus, it was hypothesized here that DPP4a may be associated with adverse cardiovascular events during the long-term follow-up period in these patients.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study population</title><p>The People&#8217;s Liberation Army General Hospital (PLAGH) is a tertiary referral center in Beijing, China. A total of 841 STEMI patients were consecutively admitted between January 2013 and September 2015 to the department of cardiology, PLAGH. All of the 803 STEMI patients who agreed to participate gave written informed consent. The study protocol was reviewed and approved by the ethics committee of the PLAGH and the Beijing Ethics Association, and is in accordance with the Declaration of Helsinki.</p><p>Blood samples were collected on the first morning after admission for all patients with acute myocardial infarction. Plasma samples were frozen at &#8722;80&#160;&#176;C until further analyses. Percutaneous coronary intervention (PCI) treatments were administered to 712 participants. Major exclusion criteria for PCI included: conditions requiring treatment with coronary artery bypass grafting (CABG) or thrombolytic therapy according to the current standard guidelines [<xref ref-type="bibr" rid="CR16">16</xref>], uncontrolled hypertension, any substantial trauma, or increased risk of severe bleeding. To enhance homogeneity of the sample and to ensure examination of a representative cohort in the context of contemporary treatment modalities, we further excluded patients with cancer (n&#160;=&#160;24; cancer can affect both DPP4a and the outcomes of interest [<xref ref-type="bibr" rid="CR17">17</xref>]), and patients who were taking a DPP4 inhibitor (n&#160;=&#160;26) or a GLP-1 analogue (n&#160;=&#160;16). Patients were followed for a median of 30&#160;months (interquartile range 23&#8211;44&#160;months), and 21 patients were lost to follow-up. Thus, the final sample size was 625 patients.</p><p>The age range of patients was 28&#8211;88&#160;years old. Participants did not experience cardiogenic shock, and survived for at least 24&#160;h after PCI treatment. STEMI events were defined as MI with typical cardiac ischemic symptoms, as well as electrocardiographic ischemic changes with ST-segment elevations of &gt;0.1&#160;mm in at least two contiguous leads, and positive cardiac troponin tests. PCI procedures were performed according to current AHA PCI standard guidelines [<xref ref-type="bibr" rid="CR18">18</xref>]. Post-procedural medications were given according to ACC/AHA guidelines and included: aspirin, clopidogrel, &#946;-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, nitrates, antidiabetic agents and statins [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec4"><title>Outcome events and follow-up</title><p>All clinical and demographic properties of the patients were recorded from hospital files and computer records. The primary endpoint for this study was a major adverse cardiac or cerebrovascular event (MACCE), defined as either: cardiovascular (CV) death, non-fatal myocardial infarction, heart failure, or stroke. Other endpoints of interest included non-CV death and repeated revascularization. Outcome status, date and etiologies were obtained from follow-up outpatient visits, inpatient clinical records of re-admitted patients, or by telephone interviews in which the moderators were blinded to patients&#8217; DPP4a. There was no adjudication. Revascularization was defined as repeated PCI or bypass grafting of either infarct-related arteries or non-infarct-related arteries, occurring due to either ischemic symptoms (stable/unstable angina or re-infarction) or detections of ischemic events by non-invasive tests. Stroke was defined using World Health Organization-defined criteria [<xref ref-type="bibr" rid="CR20">20</xref>]. Hypertension was defined as either a blood pressure level of &#8805;140/90&#160;mmHg by three separate resting sphygmomanometer measurements or the use of an anti-hypertensive agent. Throughout this article, any reference to plasma glucose concentrations pertained to measurements obtained after an overnight fast of at least 8&#160;h, occurring within 24&#160;h of admission. Patients were considered to have type-2 diabetes mellitus (T2DM) if they were previously diagnosed or used anti-diabetic agents prior to admission.</p></sec><sec id="Sec5"><title>Biochemical measurements</title><p>All biomarker measurements were performed by investigators who were blinded to patients&#8217; characteristics and outcomes. Fast plasma glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, N-terminal pro B-type natriuretic peptide (NT-proBNP), creatinine, creatine kinase-MB (CK-MB), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) levels were measured using automated enzymatic methods (Cobas<sup>&#174;</sup>, Roche, Germany). DPP4 activities were determined in EDTA-treated plasma samples by measuring rates of p-nitroaniline (pNa) cleavage from the synthetic substrate H-Gly-Pro-pNa (L1880, Bachem, Switzerland) by DPP4, as previously described [<xref ref-type="bibr" rid="CR13">13</xref>]. Briefly, 5&#160;&#181;L plasma samples were added to 150&#160;&#181;L of 50&#160;mM tris&#8211;HCl containing 1&#160;mM H-Gly-Pro-pNa. DPP4 activity were expressed as the amount of pNa cleaved per minute per liter (U/L).</p></sec><sec id="Sec6"><title>Statistical analyses</title><p>Data distributions were evaluated for normality by plotting both probability plot and quantile&#8211;quantile plot. Continuous variables were expressed as means (&#177;SD), or medians (interquartile ranges) depending on normality. Categorical variables were expressed as counts (percentages). ANOVA, Kruskal&#8211;Wallis and Chi square tests were used to compare normally distributed variables, and non-normally distributed continuous and discrete variables, respectively. To evaluate the prognostic value of DPP4a, patients were stratified into DPP4a tertiles. Survival analyses were performed with Kaplan&#8211;Meier methods with stratifications by DDP4a tertiles, and results were statistically evaluated with log-rank tests. Cox proportional hazard regression models were applied to query the data for independent predictors of outcomes. Participants were censored upon first presentation of the combined endpoint. To select variables for inclusion in multivariate analyses, univariate Cox proportional hazards models using forward variable selection methods were used. Variables were considered significant in the univariate models when <italic>p</italic>&#160;&lt;&#160;0.05. Other factors included in the multivariate models have been previously shown to associate with MACCE [<xref ref-type="bibr" rid="CR21">21</xref>]. Model 1 adjusted for age and gender. Model 2, the fully adjusted model, also adjusted for: body mass index; levels of: creatinine, triglycerides, aspartate aminotransferases, CK-MB, pro-brain natriuretic peptides, and fasting plasma glucose; hypertension; smoking; previous myocardial infarction; and use of: ACEI, ARB, statins, beta-blockers, calcium channel blockers or diuretics. All statistical tests were two-tailed and differences were considered significance if <italic>p</italic> values were less than 0.05. All analyses were performed with SPSS 13.0 software (SPSS, IL, USA).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>Demographics of the included and excluded patient populations are given in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1. No significant differences between characteristics of the two groups were observed. Demographics of the included participant populations are given in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The cohort comprised 519 men (81.9%) and 106 women (19.1%) with a mean age of 57.4&#160;&#177;&#160;11.4&#160;years. The median DPP4a was 27.49&#160;&#177;&#160;8.76&#160;U/L. No difference in activity level was found between genders (male: 27.49&#160;&#177;&#160;8.78&#160;U/L, female: 27.46&#160;&#177;&#160;8.72&#160;U/L; <italic>p</italic>&#160;=&#160;0.97), or between diabetic and non-diabetic patients (diabetic: 26.38&#160;&#177;&#160;9.21&#160;U/L, non-diabetic: 27.83&#160;&#177;&#160;8.61&#160;U/L; <italic>p</italic>&#160;=&#160;0.08). Increased DPP4a (by tertiles) negatively associated with histories of hypertension. Conversely, DPP4a positively associated with current smoking status, and levels of ALT and AST (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#160;1</label><caption><p>Patients&#8217; characteristics, stratified by DPP4a tertiles</p></caption><table-wrap-foot><p>Data are presented as mean&#160;&#177;&#160;SD, numbers (percentages) or median (interquartile range)</p><p>
<italic>ACEI</italic> angiotensin converting enzyme inhibitors, <italic>ALT</italic> alanine aminotransferase, <italic>ARB</italic> angiotensin receptor blocker, <italic>AST</italic> aspartate aminotransferase, <italic>BMI</italic> body mass index, <italic>NT-proBNP</italic> N-terminal pro B-type natriuretic peptide, <italic>CV</italic> cardiovascular, <italic>CK-MB</italic> MB isoenzyme of creatine kinase, <italic>cTNT</italic> cardiac troponin T, <italic>DPP4a</italic> plasma dipeptidyl peptidase-4 activity, <italic>FPG</italic> fasting plasma glucose, <italic>GGT</italic> g-glutamyl transferase, <italic>HF</italic> heart failure, <italic>HDL</italic> high-density lipoprotein, <italic>LDH</italic> lactate dehydrogenase, <italic>LDL</italic> low-density lipoprotein, <italic>MACCE</italic> major adverse cardiac or cerebrovascular events, <italic>MI</italic> myocardial infarction</p></table-wrap-foot></table-wrap>
</p><p>Kaplan&#8211;Meier longitudinal analyses showed that patients in the highest DPP4a tertile (DPP4a &gt;31.30&#160;U/L) had similar CV event rates and non-CV mortality rates when compared with patients in the lowest and the middle DPP4a tertiles (all log-rank tests <italic>p</italic>&#160;&gt;&#160;0.05; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Multivariate Cox proportional hazards models were used to quantify the adjusted risk of MACCE. In both unadjusted and adjusted models, DPP4a did not associate with: MACCE (adjusted HR [aHR]: 1.01, 95% CI [0.98&#8211;1.05] for 1&#160;U/L increase of DPP4a, <italic>p</italic>&#160;=&#160;0.53), CV mortality, myocardial infarction, HF readmission, stroke and repeated revascularization. In the fully-adjusted model, DPP4a did not associate with increased incidence of non-CV mortality. An additional sub-group analysis was performed to determine whether increased DPP4a was predictive of MACCE in diabetic or non-diabetic patients. One U/L increase of DPP4a associated with an increasing risk of MACCE in diabetic patients (aHR 1.16 [1.04&#8211;1.30], p&#160;=&#160;0.01), but not non-diabetic patients (aHR 0.98 [0.94&#8211;1.03], p&#160;=&#160;0.48) in the fully-adjusted models (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig.&#160;1</label><caption><p>Results of Kaplan&#8211;Meier analysis of cumulative event-free rates in STEMI patients, stratified by DPP4a tertiles. As noted, rates of CV death (<bold>a</bold>), non-CV death (<bold>b</bold>), myocardial infarction (<bold>c</bold>), heart failure (<bold>d</bold>), and stroke (<bold>e</bold>) as well as repeated revascularization free-rate (<bold>f</bold>) were not significantly different among DPP4a tertiles</p></caption><graphic xlink:href="12933_2017_553_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab2"><label>Table&#160;2</label><caption><p>Multivariable cox proportional hazards models for predicting outcomes per 1&#160;U/L increase of DPP4a</p></caption><table-wrap-foot><p>Model 1 adjusted for age and gender; Model 2 adjusted for Model 1 plus body mass index, creatinine, triglyceride, aspartate aminotransferase, CK-MB, NT-pro-brain natriuretic peptide, fasting plasma glucose, hypertension, smoking, previous myocardial infarction and use of ACEI, ARB, statin, &#946;-blocker, calcium channel blocker and diuretics</p><p>
<italic>CI</italic> confidence interval, <italic>CV</italic> cardiovascular, <italic>DPP4a</italic> plasma dipeptidyl peptidase-4 activity, <italic>HF</italic> heart failure, <italic>HR</italic> hazard ratio, <italic>MACCE</italic> major adverse cardiac or cerebrovascular events, <italic>T2DM</italic> type 2 diabetes</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>This study demonstrates a lack of evidence that DPP4a predicted MACCE in non-diabetic STEMI patients receiving PCI treatment. However, in this sample, DPP4a may be associated with MACCE in diabetic STEMI patients.</p><p>Previous studies have reported that DPP4a did not associate with hypertension in diabetic patients [<xref ref-type="bibr" rid="CR12">12</xref>], but did associate with new-onset hypertensive events [<xref ref-type="bibr" rid="CR22">22</xref>]. Our study showed that DPP4a inversely associated with hypertension. In a pre-clinical study, pharmacological inhibition of DPP4 that reduced plasma DPP4a results in improved hypertension rates [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In accordance with previous data [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>], the present study found that patients with higher DPP4a had increased liver transaminase and GGT levels. These data support the hypothesis that DPP4 serum enzymatic activity originates from the liver and is linked to insulin resistance [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Previous studies reported that hepatitis C viral infections associated with higher DPP4a [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In the current study, only one patient was concomitantly infected with hepatitis C virus (based on preoperative immunological results). Thus, the associations observed between DPP4a and liver transaminases and GGT are not related to hepatitis C virus infections in this population. Although a previous study has shown that DPP4a was higher in diabetic populations [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], this trend was not observed in the current study. However, DPP4a is reduced after MI [<xref ref-type="bibr" rid="CR13">13</xref>], thus diabetic patients may have more severe DPP4a reductions after STEMI than non-diabetic patients.</p><p>DPP4a is considered a potential prognostic marker for cardiovascular diseases. Higher plasma DPP4a was associated with worsened cardiovascular outcomes in heart failure patients [<xref ref-type="bibr" rid="CR11">11</xref>]. Additionally, DPP4a predicted atherosclerotic events in a healthy cohort [<xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, inhibition of DPP4 gene products, which down-regulated DPP4a [<xref ref-type="bibr" rid="CR32">32</xref>], decreased mortality after myocardial infarction in diabetic rats [<xref ref-type="bibr" rid="CR33">33</xref>]. Expression of the DPP4 gene may affect MACCE of STEMI patients in a GLP-1-dependent way. Bioactive GLP-1 was degraded at its N terminus by DPP4 proteins, and inhibition of DPP4 increased expression of active GLP-1 [<xref ref-type="bibr" rid="CR34">34</xref>]. GLP-1 could protect the heart from ischemic-reperfusion injury. In humans and in animal models, GLP-1 beneficially affected cardiac contractility, blood pressure and cardiac output [<xref ref-type="bibr" rid="CR35">35</xref>]. GLP-1 improved outcomes after experimentally-induced myocardial infarction [<xref ref-type="bibr" rid="CR36">36</xref>]. Our group previously found that GLP-1 analog use before PCI associated with improved left ventricular ejection fraction rates in MI patients after a 3-month follow-up [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Moreover, DPP4 protein has additional substrates that participate in responses to ischemic heart disease, such as stromal cell-derived factor-1 alpha (SDF1&#945;), neuropeptide Y and substance P [<xref ref-type="bibr" rid="CR39">39</xref>]. The plasma levels of these substrates associated with adverse events after MI [<xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR42">42</xref>]. Inhibition of DPP4 attenuated post-MI cardiac dysfunction and adverse remodeling events in rats [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] and mice [<xref ref-type="bibr" rid="CR6">6</xref>]. An earlier study from our group identified that DPP4a associated with no-reflow and in-hospital major bleeding events in STEMI patients [<xref ref-type="bibr" rid="CR13">13</xref>]. We therefore hypothesized that DPP4a associated with long-term prognoses in STEMI patients.</p><p>The data reported here showed that DPP4a did not associated with long-term MACCE in STEMI patients. Although circulating DPP4a was changed in MI patients, it did not predict long-term prognoses. In fact, use of a DPP4 inhibitor, which regulated DPP4a, failed to decrease the incidence of MACCE in humans. Three large randomized clinical trials (SAVOR TIMI, NCT01107886; EXAMINE, NCT00968708; and TECOS, NCT00790205) demonstrated that DPP4 inhibitors did not decrease MACCE risk in diabetic patients with CV diseases [<xref ref-type="bibr" rid="CR45">45</xref>]. In a recent meta-analysis, DPP4 inhibitors did not affect mortality and CV events [<xref ref-type="bibr" rid="CR46">46</xref>]. DPP4 may play distinct roles in different aspects of cardiovascular disease that collectively lead to an overall neutral effect on cardiovascular events in STEMI patients. A recent study reported that increased circulating DPP4 levels positively and independently associated with coronary artery disease, even in the absence of DM [<xref ref-type="bibr" rid="CR31">31</xref>]. These data conflict with the present study. However the previous study was a cross-sectional design and did not study long-term outcomes. Moreover acute MI and unstable angina pectoris were not distinguished in the previous study, while the current study only included STEMI patients. Given these fundamental differences, it is reasonable that the results differed in the two studies.</p><p>Diabetes has been consistently associated with more severe myocardial infarction. Indeed, diabetic patients have shown more than twofold greater incidence of acute coronary syndromes and cardiovascular diseases, two to fourfold greater incidence of cardiovascular disease-related mortality, and larger infarct sizes compared to non-diabetic patients [<xref ref-type="bibr" rid="CR47">47</xref>]. Moreover, diabetes confers an approximately threefold greater odds of post-STEMI right ventricular dysfunction, leading to a worsened prognosis for diabetic MI patients [<xref ref-type="bibr" rid="CR48">48</xref>]. Since DPP4 is a therapeutic target for diabetes, most studies on DPP4 are carried out in diabetic patients. A previous study found that circulating DPP4 was elevated in type 2 diabetic patients, regardless of coronary artery disease status [<xref ref-type="bibr" rid="CR31">31</xref>], which associated with subclinical left ventricular dysfunction [<xref ref-type="bibr" rid="CR12">12</xref>] and subclinical atherosclerosis [<xref ref-type="bibr" rid="CR9">9</xref>] in these patients. DPP4 inhibitor treatments associated with lower risks of mortality as well as MI and ischemic stroke in diabetic patients with pre-existing heart failures [<xref ref-type="bibr" rid="CR49">49</xref>]. Additionally, vildagliptin, a DPP4 inhibitor, increased survival rates of diabetic, but not non-diabetic mice [<xref ref-type="bibr" rid="CR33">33</xref>], suggesting that DPP4 may have a unique role in diabetes. In the current study a subgroup analysis was performed on DPP4a and MACCE in diabetic and non-diabetic STEMI patients. We found that higher DPP4a associated with MACCE in 149 diabetic STEMI patients after adjustment for confounding factors. Given that this study was not powered for diabetic patients (only about 25% of the population was diabetic), a strong conclusion cannot be drawn. The predictive effects of plasma markers may be affected by co-morbid diabetes [<xref ref-type="bibr" rid="CR50">50</xref>]. Additionally, in the above described studies DPP4 had a positive prognostic role in diabetic patients, and our results were obtained after correcting for all confounding factors. Thus, these data support that a positive correlation exists between DPP4a and MACCE in diabetic patients. Nonetheless, a future study is required that is powered to answer this question.</p></sec><sec id="Sec9"><title>Limitations</title><p>Some limitations existed in the current study. First, the diabetic STEMI patient sub-population was small, as the study was not powered to study this sub-group. Second, the study was limited to inclusion of selected patients from just one center. Third, DPP4 activity was measured at a single time point; additional blood specimens were not collected at other times during patients&#8217; hospital stays or follow-up visits. Peri- or post-operative dynamic changes of DPP4a may provide additional contextual information regarding the role of DPP4 in diabetic STEMI patients.</p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusions</title><p>In summary, the current study showed that circulating DPP4a was not associated with risks of MACCE in non-diabetic STEMI patients. However, DPP4a may have associated with MACCE in diabetic STEMI patients. This possibility will be explored in a future large-sample multi-center trial.</p></sec></body><back><app-group><app id="App1"><sec id="Sec11"><title>Additional file</title><p>
<media position="anchor" xlink:href="12933_2017_553_MOESM1_ESM.docx" id="MOESM1"><caption><p>
<bold>Additional file 1: Table S1.</bold> The characteristics of STEMI patients between included and excluded patients.</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>CV</term><def><p>cardiovascular</p></def></def-item><def-item><term>DPP4</term><def><p>dipeptidyl peptidase-4</p></def></def-item><def-item><term>DPP4a</term><def><p>plasma DPP4 activity</p></def></def-item><def-item><term>HR</term><def><p>hazard ratio</p></def></def-item><def-item><term>MACCE</term><def><p>major adverse cardiac or cerebrovascular events</p></def></def-item><def-item><term>PCI</term><def><p>percutaneous coronary intervention</p></def></def-item><def-item><term>STEMI</term><def><p>ST-segment elevation myocardial infarction</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s12933-017-0553-3) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Authors&#8217; contributions</title><p>JWL was responsible for the conception and design of the study. WRC and QY analyzed the data. BL wrote the manuscript. HZ contributed to the discussion and reviewed/edited the manuscript. YZ and TWH analyzed the data and contributed to the discussion. YDC reviewed/edited the manuscript and gave the final approval for the manuscript. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>Not applicable.</p></sec><sec id="FPar2"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p>All study data will be available on request.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>All authors consented to the publication of the study data.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p>The study protocol and all procedures received approval from the ethics committee of the PLAGH and the Beijing Ethics Association. Studies conformed with the Declaration of Helsinki. Informed consent documents were obtained from all subjects prior to any study related procedures or measurements.</p></sec><sec id="FPar6"><title>Funding</title><p>This study was supported by the China Postdoctoral Science Foundation (2016M603025) and the Pilot Foundation of the Beijing Lisheng Cardiovascular Health Foundation (LHJJ201611827).</p></sec><sec id="FPar7"><title>Publisher&#8217;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemann</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Stephan</surname><given-names>M</given-names></name><name><surname>von Horsten</surname><given-names>S</given-names></name></person-group><article-title>Cut to the chase: a review of CD26/dipeptidyl peptidase-4&#8217;s (DPP4) entanglement in the immune system</article-title><source>Clin Exp Immunol</source><year>2016</year><volume>185</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/cei.12781</pub-id><?supplied-pmid 26919392?><pub-id pub-id-type="pmid">26919392</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Maiseyeu</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name><name><surname>Rajagopalan</surname><given-names>S</given-names></name></person-group><article-title>DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition</article-title><source>Circ Res</source><year>2015</year><volume>116</volume><issue>8</issue><fpage>1491</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305665</pub-id><?supplied-pmid 25858071?><pub-id pub-id-type="pmid">25858071</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Hirshberg</surname><given-names>B</given-names></name><name><surname>Ohman</surname><given-names>P</given-names></name><name><surname>Frederich</surname><given-names>R</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Hoffman</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307684</pub-id><?supplied-pmid 23992601?><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Avogaro</surname><given-names>A</given-names></name><name><surname>Degli Esposti</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name><name><surname>Saragoni</surname><given-names>S</given-names></name><name><surname>Buda</surname><given-names>S</given-names></name><name><surname>Rosano</surname><given-names>G</given-names></name><name><surname>Pecorelli</surname><given-names>S</given-names></name><name><surname>Pani</surname><given-names>L</given-names></name></person-group><article-title>Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>36</issue><fpage>2454</fpage><lpage>2462</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv301</pub-id><?supplied-pmid 26112890?><pub-id pub-id-type="pmid">26112890</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Vandvik</surname><given-names>PO</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Bala</surname><given-names>MM</given-names></name><name><surname>Sohani</surname><given-names>ZN</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies</article-title><source>BMJ</source><year>2016</year><volume>352</volume><fpage>i610</fpage><pub-id pub-id-type="doi">10.1136/bmj.i610</pub-id><?supplied-pmid 26888822?><pub-id pub-id-type="pmid">26888822</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauve</surname><given-names>M</given-names></name><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Momen</surname><given-names>MA</given-names></name><name><surname>Zhou</surname><given-names>YQ</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><issue>4</issue><fpage>1063</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.2337/db09-0955</pub-id><?supplied-pmid 20097729?><pub-id pub-id-type="pmid">20097729</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Sakakura</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Arao</surname><given-names>K</given-names></name><name><surname>Katayama</surname><given-names>T</given-names></name><name><surname>Funayama</surname><given-names>H</given-names></name><name><surname>Sugawara</surname><given-names>Y</given-names></name><name><surname>Mitsuhashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients</article-title><source>Heart Vessels</source><year>2015</year><volume>30</volume><issue>5</issue><fpage>696</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1007/s00380-014-0509-4</pub-id><?supplied-pmid 24736945?><pub-id pub-id-type="pmid">24736945</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulvihill</surname><given-names>EE</given-names></name><name><surname>Varin</surname><given-names>EM</given-names></name><name><surname>Gladanac</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>JE</given-names></name><name><surname>Ussher</surname><given-names>JR</given-names></name><name><surname>Baggio</surname><given-names>LL</given-names></name><name><surname>Yusta</surname><given-names>B</given-names></name><name><surname>Ayala</surname><given-names>J</given-names></name><name><surname>Burmeister</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis</article-title><source>Cell Metab</source><year>2017</year><volume>25</volume><issue>1</issue><fpage>152</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.10.007</pub-id><?supplied-pmid 27839908?><pub-id pub-id-type="pmid">27839908</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>TP</given-names></name><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>Yang</surname><given-names>LX</given-names></name><name><surname>Qin</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>HB</given-names></name></person-group><article-title>Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study</article-title><source>Atherosclerosis</source><year>2015</year><volume>242</volume><issue>2</issue><fpage>580</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.07.042</pub-id><?supplied-pmid 26318108?><pub-id pub-id-type="pmid">26318108</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>TP</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Baskota</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Tian</surname><given-names>HM</given-names></name><name><surname>Ran</surname><given-names>XW</given-names></name></person-group><article-title>Increased plasma DPP4 activities predict new-onset atherosclerosis in association with its proinflammatory effects in Chinese over a four year period: a prospective study</article-title><source>Atherosclerosis</source><year>2014</year><volume>235</volume><issue>2</issue><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.05.956</pub-id><?supplied-pmid 24968315?><pub-id pub-id-type="pmid">24968315</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>dos Santos</surname><given-names>L</given-names></name><name><surname>Salles</surname><given-names>TA</given-names></name><name><surname>Arruda-Junior</surname><given-names>DF</given-names></name><name><surname>Campos</surname><given-names>LC</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Barreto</surname><given-names>AL</given-names></name><name><surname>Antonio</surname><given-names>EL</given-names></name><name><surname>Mansur</surname><given-names>AJ</given-names></name><name><surname>Tucci</surname><given-names>PJ</given-names></name><name><surname>Krieger</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure</article-title><source>Circ Heart Fail</source><year>2013</year><volume>6</volume><issue>5</issue><fpage>1029</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.112.000057</pub-id><?supplied-pmid 23894014?><pub-id pub-id-type="pmid">23894014</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravassa</surname><given-names>S</given-names></name><name><surname>Barba</surname><given-names>J</given-names></name><name><surname>Coma-Canella</surname><given-names>I</given-names></name><name><surname>Huerta</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>B</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Diez</surname><given-names>J</given-names></name></person-group><article-title>The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-143</pub-id><?supplied-pmid 24099410?><pub-id pub-id-type="pmid">24099410</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JW</given-names></name><name><surname>Chen</surname><given-names>YD</given-names></name><name><surname>Chen</surname><given-names>WR</given-names></name><name><surname>Jing</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name></person-group><article-title>Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>39412</fpage><pub-id pub-id-type="doi">10.1038/srep39412</pub-id><?supplied-pmid 28000723?><pub-id pub-id-type="pmid">28000723</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niccoli</surname><given-names>G</given-names></name><name><surname>Kharbanda</surname><given-names>RK</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Banning</surname><given-names>AP</given-names></name></person-group><article-title>No-reflow: again prevention is better than treatment</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>20</issue><fpage>2449</fpage><lpage>2455</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq299</pub-id><?supplied-pmid 20837571?><pub-id pub-id-type="pmid">20837571</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellaton</surname><given-names>C</given-names></name><name><surname>Cayla</surname><given-names>G</given-names></name><name><surname>Silvain</surname><given-names>J</given-names></name><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>P</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Pollack</surname><given-names>C</given-names><suffix>Jr</suffix></name><name><surname>Kerneis</surname><given-names>M</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized acute myocardial infarction treated with primary angioplasty and intravenous enoxaparin or unfractionated heparin to lower ischemic and bleeding events at short- and long-term follow-up trial</article-title><source>Am Heart J</source><year>2015</year><volume>170</volume><issue>4</issue><fpage>778</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2015.05.021</pub-id><?supplied-pmid 26386802?><pub-id pub-id-type="pmid">26386802</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Gara</surname><given-names>PT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Ettinger</surname><given-names>SM</given-names></name><name><surname>Fang</surname><given-names>JC</given-names></name><name><surname>Fesmire</surname><given-names>FM</given-names></name><name><surname>Franklin</surname><given-names>BA</given-names></name><etal/></person-group><article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>61</volume><issue>4</issue><fpage>e78</fpage><lpage>e140</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.11.019</pub-id><?supplied-pmid 23256914?><pub-id pub-id-type="pmid">23256914</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javidroozi</surname><given-names>M</given-names></name><name><surname>Zucker</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>WT</given-names></name></person-group><article-title>Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer</article-title><source>Dis Markers</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>309</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1155/2012/706745</pub-id><?supplied-pmid 22674411?><pub-id pub-id-type="pmid">22674411</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Blankenship</surname><given-names>JC</given-names></name><name><surname>Bailey</surname><given-names>SR</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><name><surname>Cercek</surname><given-names>B</given-names></name><name><surname>Chambers</surname><given-names>CE</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><name><surname>Hollenberg</surname><given-names>SM</given-names></name><etal/></person-group><article-title>2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions</article-title><source>Circulation</source><year>2011</year><volume>124</volume><issue>23</issue><fpage>2574</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1161/CIR.0b013e31823a5596</pub-id><?supplied-pmid 22064598?><pub-id pub-id-type="pmid">22064598</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Fleisher</surname><given-names>LA</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Lange</surname><given-names>RA</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Mauri</surname><given-names>L</given-names></name><etal/></person-group><article-title>2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery</article-title><source>Circulation</source><year>2016</year><volume>134</volume><issue>10</issue><fpage>e123</fpage><lpage>e155</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000404</pub-id><?supplied-pmid 27026020?><pub-id pub-id-type="pmid">27026020</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aho</surname><given-names>K</given-names></name><name><surname>Harmsen</surname><given-names>P</given-names></name><name><surname>Hatano</surname><given-names>S</given-names></name><name><surname>Marquardsen</surname><given-names>J</given-names></name><name><surname>Smirnov</surname><given-names>VE</given-names></name><name><surname>Strasser</surname><given-names>T</given-names></name></person-group><article-title>Cerebrovascular disease in the community: results of a WHO collaborative study</article-title><source>Bull World Health Organ</source><year>1980</year><volume>58</volume><issue>1</issue><fpage>113</fpage><lpage>130</lpage><?supplied-pmid 6966542?><pub-id pub-id-type="pmid">6966542</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zittermann</surname><given-names>A</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Dreier</surname><given-names>J</given-names></name><name><surname>Knabbe</surname><given-names>C</given-names></name><name><surname>Gummert</surname><given-names>JF</given-names></name><name><surname>Borgermann</surname><given-names>J</given-names></name></person-group><article-title>Vitamin D status and the risk of major adverse cardiac and cerebrovascular events in cardiac surgery</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>18</issue><fpage>1358</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs468</pub-id><?supplied-pmid 23315905?><pub-id pub-id-type="pmid">23315905</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name></person-group><article-title>Increased plasma DPP4 activity predicts new-onset hypertension in Chinese over a 4-year period: possible associations with inflammation and oxidative stress</article-title><source>J Hum Hypertens</source><year>2015</year><volume>29</volume><issue>7</issue><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1038/jhh.2014.111</pub-id><?supplied-pmid 25411054?><pub-id pub-id-type="pmid">25411054</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname><given-names>H</given-names></name><name><surname>Bando</surname><given-names>YK</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Aoyama</surname><given-names>M</given-names></name><name><surname>Monji</surname><given-names>A</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name></person-group><article-title>A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis</article-title><source>J Mol Cell Cardiol</source><year>2016</year><volume>98</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.06.066</pub-id><?supplied-pmid 27374118?><pub-id pub-id-type="pmid">27374118</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aroor</surname><given-names>AR</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name><name><surname>Bender</surname><given-names>SB</given-names></name><name><surname>Nistala</surname><given-names>R</given-names></name><name><surname>Garro</surname><given-names>M</given-names></name><name><surname>Mugerfeld</surname><given-names>I</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Johnson</surname><given-names>MS</given-names></name><name><surname>Salam</surname><given-names>M</given-names></name><name><surname>Whaley-Connell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><issue>7</issue><fpage>2501</fpage><lpage>2513</lpage><pub-id pub-id-type="doi">10.1210/en.2013-1096</pub-id><?supplied-pmid 23653460?><pub-id pub-id-type="pmid">23653460</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaslov</surname><given-names>K</given-names></name><name><surname>Bulum</surname><given-names>T</given-names></name><name><surname>Kne&#382;evi&#263;-&#262;u&#263;a</surname><given-names>J</given-names></name><name><surname>Duvnjak</surname><given-names>L</given-names></name></person-group><article-title>Fasting serum dipeptidyl peptidase-4 activity is independently associated with alanine aminotransferase in type 1 diabetic patients</article-title><source>Clin Biochem</source><year>2015</year><volume>48</volume><issue>1&#8211;2</issue><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2014.10.006</pub-id><?supplied-pmid 25445232?><pub-id pub-id-type="pmid">25445232</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aso</surname><given-names>Y</given-names></name><name><surname>Terasawa</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Jojima</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Iijima</surname><given-names>T</given-names></name><name><surname>Kawagoe</surname><given-names>Y</given-names></name><name><surname>Mikami</surname><given-names>S</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Inukai</surname><given-names>T</given-names></name><etal/></person-group><article-title>The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes</article-title><source>Transl Res</source><year>2013</year><volume>162</volume><issue>5</issue><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2013.07.011</pub-id><?supplied-pmid 23994650?><pub-id pub-id-type="pmid">23994650</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SA</given-names></name><name><surname>Kim</surname><given-names>YR</given-names></name><name><surname>Yang</surname><given-names>EJ</given-names></name><name><surname>Kwon</surname><given-names>E-J</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>DB</given-names></name><name><surname>Oh</surname><given-names>B-C</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Heo</surname><given-names>ST</given-names></name><etal/></person-group><article-title>CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>6</issue><fpage>2553</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-4288</pub-id><?supplied-pmid 23539735?><pub-id pub-id-type="pmid">23539735</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firneisz</surname><given-names>G</given-names></name><name><surname>Varga</surname><given-names>T</given-names></name><name><surname>Lengyel</surname><given-names>G</given-names></name><name><surname>Feher</surname><given-names>J</given-names></name><name><surname>Ghyczy</surname><given-names>D</given-names></name><name><surname>Wichmann</surname><given-names>B</given-names></name><name><surname>Selmeci</surname><given-names>L</given-names></name><name><surname>Tulassay</surname><given-names>Z</given-names></name><name><surname>Racz</surname><given-names>K</given-names></name><name><surname>Somogyi</surname><given-names>A</given-names></name></person-group><article-title>Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>8</issue><fpage>e12226</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0012226</pub-id><?supplied-pmid 20805868?><pub-id pub-id-type="pmid">20805868</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragab</surname><given-names>D</given-names></name><name><surname>Laird</surname><given-names>M</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Casrouge</surname><given-names>A</given-names></name><name><surname>Mamdouh</surname><given-names>R</given-names></name><name><surname>Abass</surname><given-names>A</given-names></name><name><surname>Shenawy</surname><given-names>DE</given-names></name><name><surname>Shebl</surname><given-names>AM</given-names></name><name><surname>Elkashef</surname><given-names>WF</given-names></name><name><surname>Zalata</surname><given-names>KR</given-names></name><etal/></person-group><article-title>CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients</article-title><source>Cytokine</source><year>2013</year><volume>63</volume><issue>2</issue><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2013.04.016</pub-id><?supplied-pmid 23664274?><pub-id pub-id-type="pmid">23664274</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>EG</given-names></name><name><surname>Decalf</surname><given-names>J</given-names></name><name><surname>Casrouge</surname><given-names>A</given-names></name><name><surname>Masur</surname><given-names>H</given-names></name><name><surname>Kottilil</surname><given-names>S</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name></person-group><article-title>Dynamic changes of post-translationally modified forms of CXCL10 and soluble DPP4 in HCV subjects receiving interferon-free therapy</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>7</issue><fpage>e0133236</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0133236</pub-id><?supplied-pmid 26181438?><pub-id pub-id-type="pmid">26181438</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><etal/></person-group><article-title>Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>9</issue><fpage>e0163027</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0163027</pub-id><?supplied-pmid 27654253?><pub-id pub-id-type="pmid">27654253</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Dorso</surname><given-names>C</given-names></name><name><surname>Kopcho</surname><given-names>L</given-names></name><name><surname>Locke</surname><given-names>G</given-names></name><name><surname>Langish</surname><given-names>R</given-names></name><name><surname>Harstad</surname><given-names>E</given-names></name><name><surname>Shipkova</surname><given-names>P</given-names></name><name><surname>Marcinkeviciene</surname><given-names>J</given-names></name><name><surname>Hamann</surname><given-names>L</given-names></name><name><surname>Kirby</surname><given-names>MS</given-names></name></person-group><article-title>Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor</article-title><source>BMC Pharmacol</source><year>2012</year><volume>12</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1471-2210-12-2</pub-id><?supplied-pmid 22475049?><pub-id pub-id-type="pmid">22475049</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murase</surname><given-names>H</given-names></name><name><surname>Kuno</surname><given-names>A</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Tanno</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>T</given-names></name><name><surname>Kouzu</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>S</given-names></name><name><surname>Tobisawa</surname><given-names>T</given-names></name><name><surname>Ogasawara</surname><given-names>M</given-names></name><name><surname>Nishizawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0264-6</pub-id><?supplied-pmid 26259714?><pub-id pub-id-type="pmid">26259714</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieffer</surname><given-names>TJ</given-names></name><name><surname>Habener</surname><given-names>JF</given-names></name></person-group><article-title>The glucagon-like peptides</article-title><source>Endocr Rev</source><year>1999</year><volume>20</volume><issue>6</issue><fpage>876</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1210/edrv.20.6.0385</pub-id><?supplied-pmid 10605628?><pub-id pub-id-type="pmid">10605628</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hocher</surname><given-names>B</given-names></name><name><surname>Reichetzeder</surname><given-names>C</given-names></name><name><surname>Alter</surname><given-names>ML</given-names></name></person-group><article-title>Renal and cardiac effects of DPP4 inhibitors&#8212;from preclinical development to clinical research</article-title><source>Kidney Blood Press Res</source><year>2012</year><volume>36</volume><issue>1</issue><fpage>65</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1159/000339028</pub-id><?supplied-pmid 22947920?><pub-id pub-id-type="pmid">22947920</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyan-Ashraf</surname><given-names>MH</given-names></name><name><surname>Momen</surname><given-names>MA</given-names></name><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Sadi</surname><given-names>AM</given-names></name><name><surname>Zhou</surname><given-names>YQ</given-names></name><name><surname>Riazi</surname><given-names>AM</given-names></name><name><surname>Baggio</surname><given-names>LL</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><issue>4</issue><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.2337/db08-1193</pub-id><?supplied-pmid 19151200?><pub-id pub-id-type="pmid">19151200</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WR</given-names></name><name><surname>Hu</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>YD</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Ning</surname><given-names>QX</given-names></name></person-group><article-title>Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention</article-title><source>Am Heart J</source><year>2015</year><volume>170</volume><issue>5</issue><fpage>845</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2015.07.014</pub-id><?supplied-pmid 26542491?><pub-id pub-id-type="pmid">26542491</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WR</given-names></name><name><surname>Shen</surname><given-names>XQ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YD</given-names></name><name><surname>Hu</surname><given-names>SY</given-names></name><name><surname>Qian</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name></person-group><article-title>Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction</article-title><source>Endocrine</source><year>2016</year><volume>52</volume><issue>3</issue><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1007/s12020-015-0798-0</pub-id><?supplied-pmid 26573925?><pub-id pub-id-type="pmid">26573925</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Piao</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name></person-group><article-title>Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease&#8212;recent insights focusing on angiogenesis and neovascularization</article-title><source>Circ J.</source><year>2017</year><volume>81</volume><issue>6</issue><fpage>770</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-16-1326</pub-id><?supplied-pmid 28344207?><pub-id pub-id-type="pmid">28344207</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortunato</surname><given-names>O</given-names></name><name><surname>Spinetti</surname><given-names>G</given-names></name><name><surname>Specchia</surname><given-names>C</given-names></name><name><surname>Cangiano</surname><given-names>E</given-names></name><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Madeddu</surname><given-names>P</given-names></name></person-group><article-title>Migratory activity of circulating progenitor cells and serum SDF-1&#945; predict adverse events in patients with myocardial infarction</article-title><source>Cardiovasc Res</source><year>2013</year><volume>100</volume><issue>2</issue><fpage>192</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt153</pub-id><?supplied-pmid 23761401?><pub-id pub-id-type="pmid">23761401</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuculi</surname><given-names>F</given-names></name><name><surname>Herring</surname><given-names>N</given-names></name><name><surname>De Caterina</surname><given-names>AR</given-names></name><name><surname>Banning</surname><given-names>AP</given-names></name><name><surname>Prendergast</surname><given-names>BD</given-names></name><name><surname>Forfar</surname><given-names>JC</given-names></name><name><surname>Choudhury</surname><given-names>RP</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name><name><surname>Kharbanda</surname><given-names>RK</given-names></name></person-group><article-title>Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction</article-title><source>Heart</source><year>2013</year><volume>99</volume><issue>16</issue><fpage>1198</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2012-303443</pub-id><?supplied-pmid 23403409?><pub-id pub-id-type="pmid">23403409</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>LL</given-names></name><name><surname>Sandhu</surname><given-names>JK</given-names></name><name><surname>Narayan</surname><given-names>H</given-names></name><name><surname>Quinn</surname><given-names>PA</given-names></name><name><surname>Squire</surname><given-names>IB</given-names></name><name><surname>Davies</surname><given-names>JE</given-names></name><name><surname>Struck</surname><given-names>J</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Maisel</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name></person-group><article-title>Pro-substance p for evaluation of risk in acute myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>64</volume><issue>16</issue><fpage>1698</fpage><lpage>1707</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.05.074</pub-id><?supplied-pmid 25323258?><pub-id pub-id-type="pmid">25323258</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connelly</surname><given-names>KA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Advani</surname><given-names>A</given-names></name><name><surname>Advani</surname><given-names>SL</given-names></name><name><surname>Thai</surname><given-names>K</given-names></name><name><surname>Yuen</surname><given-names>DA</given-names></name><name><surname>Gilbert</surname><given-names>RE</given-names></name></person-group><article-title>DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes</article-title><source>Cardiovasc Ther</source><year>2013</year><volume>31</volume><issue>5</issue><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/1755-5922.12005</pub-id><?supplied-pmid 22963483?><pub-id pub-id-type="pmid">22963483</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apaijai</surname><given-names>N</given-names></name><name><surname>Inthachai</surname><given-names>T</given-names></name><name><surname>Lekawanvijit</surname><given-names>S</given-names></name><name><surname>Chattipakorn</surname><given-names>SC</given-names></name><name><surname>Chattipakorn</surname><given-names>N</given-names></name></person-group><article-title>Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction</article-title><source>J Endocrinol</source><year>2016</year><volume>229</volume><issue>3</issue><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1530/JOE-16-0096</pub-id><?supplied-pmid 27044778?><pub-id pub-id-type="pmid">27044778</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosal</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>B</given-names></name></person-group><article-title>Gliptins and cardiovascular outcomes: a comparative and critical analysis after TECOS</article-title><source>J Diabetes Res</source><year>2016</year><volume>2016</volume><fpage>1643496</fpage><pub-id pub-id-type="doi">10.1155/2016/1643496</pub-id><?supplied-pmid 26649315?><pub-id pub-id-type="pmid">26649315</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarese</surname><given-names>G</given-names></name><name><surname>D&#8217;Amore</surname><given-names>C</given-names></name><name><surname>Federici</surname><given-names>M</given-names></name><name><surname>De Martino</surname><given-names>F</given-names></name><name><surname>Dellegrottaglie</surname><given-names>S</given-names></name><name><surname>Marciano</surname><given-names>C</given-names></name><name><surname>Ferrazzano</surname><given-names>F</given-names></name><name><surname>Losco</surname><given-names>T</given-names></name><name><surname>Lund</surname><given-names>LH</given-names></name><name><surname>Trimarco</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis</article-title><source>Int J Cardiol</source><year>2016</year><volume>220</volume><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.06.208</pub-id><?supplied-pmid 27390996?><pub-id pub-id-type="pmid">27390996</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lejay</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>John</surname><given-names>R</given-names></name><name><surname>Van</surname><given-names>JA</given-names></name><name><surname>Barr</surname><given-names>M</given-names></name><name><surname>Thaveau</surname><given-names>F</given-names></name><name><surname>Chakfe</surname><given-names>N</given-names></name><name><surname>Geny</surname><given-names>B</given-names></name><name><surname>Scholey</surname><given-names>JW</given-names></name></person-group><article-title>Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus</article-title><source>J Mol Cell Cardiol</source><year>2016</year><volume>91</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.12.020</pub-id><?supplied-pmid 26718721?><pub-id pub-id-type="pmid">26718721</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roifman</surname><given-names>I</given-names></name><name><surname>Ghugre</surname><given-names>N</given-names></name><name><surname>Zia</surname><given-names>MI</given-names></name><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Zavodni</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>GA</given-names></name><name><surname>Connelly</surname><given-names>KA</given-names></name></person-group><article-title>Diabetes is an independent predictor of right ventricular dysfunction post ST-elevation myocardial infarction</article-title><source>Cardiovasc Diabetol</source><year>2016</year><volume>15</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0352-2</pub-id><?supplied-pmid 26892325?><pub-id pub-id-type="pmid">26892325</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>SM</given-names></name><name><surname>Chen</surname><given-names>HT</given-names></name><name><surname>Kuo</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Shih</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure</article-title><source>Heart</source><year>2017</year><volume>103</volume><issue>6</issue><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2016-309687</pub-id><?supplied-pmid 27647170?><pub-id pub-id-type="pmid">27647170</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Yuan</surname><given-names>SS</given-names></name><name><surname>Yu</surname><given-names>CG</given-names></name><name><surname>Wang</surname><given-names>ZW</given-names></name><name><surname>Lang</surname><given-names>JN</given-names></name><name><surname>Feng</surname><given-names>YM</given-names></name></person-group><article-title>Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients</article-title><source>Cardiovasc Diabetol</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>132</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0450-1</pub-id><?supplied-pmid 27620179?><pub-id pub-id-type="pmid">27620179</pub-id></element-citation></ref></ref-list></back></article>